A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Bart KeymeulenAndré van MaurikDave InmanJoão OliveiraRene McLaughlinRachel M GittelmanBart O RoepPieter GillardRobert HilbrandsFrans K GorusChantal MathieuUrsule Van de VeldeNicolas WisniackiAntonella NapolitanoPublished in: Diabetologia (2020)
The study was funded by GlaxoSmithKline. Graphical abstract.